Quantcast
Channel: MassBio Upcoming Events
Viewing all 2057 articles
Browse latest View live

YEi Start in France: Grow your business in France, a gateway to Europe!

0
0

The Office for Science & Technology of the French Embassy in the United States is pleased to announce the launch of the 10th edition of the Young Enterprise initiative (YEi Start in France), an accelerator program designed to help American entrepreneurs start and grow their business in France and Europe. This initiative offers to the best startups of the competition training sessions in the U.S. and in Paris on how to do business in France, as well as an immersion week in France for the overall winners. This week includes personalized business connection and meetings fitted to the needs of the startups and access to the best French resources (competitive clusters, large research infrastructures, etc.). For more information, visit www.yeifrance.com.  

Applications to the competition are now open HERE.

The deadline is May 27, 2015.


YEi Start in France: Grow your business in France, a gateway to Europe!

0
0

The Office for Science & Technology of the French Embassy in the United States is pleased to announce the launch of the 10th edition of the Young Enterprise initiative (YEi Start in France), an accelerator program designed to help American entrepreneurs start and grow their business in France and Europe. This initiative offers to the best startups of the competition training sessions in the U.S. and in Paris on how to do business in France, as well as an immersion week in France for the overall winners. This week includes personalized business connection and meetings fitted to the needs of the startups and access to the best French resources (competitive clusters, large research infrastructures, etc.). For more information, visit www.yeifrance.com.  

Applications to the competition are now open HERE.

The deadline is May 27, 2015.

Boston College- Computerized Systems in Clinical Research (NS 14503)

0
0

*This course consists of a single three-hour session on Wednesday, May 27th from 6-9pm.

The rapid adoption of computerized  systems in the management of clinical trials is quickly changing not only the dynamics of clinical trials but also redefining the roles of individuals working in the field. While the focus of a clinical trial will always ultimately be on the safety of the patients, eClinical applications now impact everything from case report form collection, to how often sites are monitored, to communication with the patients. This course focuses on understanding how sponsors, contract research organizations, hospitals, data management centers, universities, clinical investigators and you are being impacted by the movement to eClinical applications.  While the instructor will be showing various computer applications as part of the course, students will not be hands-on, will not need computers nor need to be "tech-savvy".  The goal of the course is to exposure you to the eClinical applications that you will most likely work with as a CRA or CRC.
 
Pre/co-requisite: Project Management in Clinical Research or Essentials of Initiating Clinical Research.

2015 ABFO National Conference

0
0

Join us in BOSTON for the 26th Annual
ABFO Conference!

 ABFO is pleased to announce that 
Vin Milano, 
CEO of Idera Pharmaceuticals, Inc.
has joined our Conference lineup as a Featured Keynote Speaker

View the proposed conference agenda HERE.

Learn more & register here!

 

DLA Piper Office Hours at District Hall

Deadline: Synthetic Biology CAREER FAIR at the iGEM Giant Jamboree (exhibitor registration deadline)

0
0

Synthetic Biology Career Fair at the iGEM Giant Jamboree

***Deadline: Register by May 22, 2015 to exhibit at the career fair!

As part of the iGEM 2015 Giant Jamboree weekend, iGEM is hosting a career fair for the synthetic biology community. This unique opportunity offers you a chance to meet with our talented pool of iGEM participants and discuss career opportunities.  The event features a career fair format with the opportunity for you to address attendees at the start of the event with you message and needs. Click here to learn more. 

  • Companies looking to hire can connect with our large community of highly knowledgeable and talented participants working in synthetic biology.
  • Universities with synthetic biology programs are invited to exhibit and promote their school, program and post-doc or graduate openings to the iGEM attendees.

For more information on this event and how to participate please contact us at hq@igem.org

 

About The iGEM Program and Giant Jamboree

iGEM, the International Genetically Engineered Machine Competition, a non-profit organization and a community of over 18,000 young scientists and leaders in synthetic biology. Inspiring learning and innovation in synthetic biology through competition, the iGEM program is the premiere synthetic biology competition for both university and high school students.

Our main event, the Giant Jamboree (held on September 24-28, 2015, Boston, MA), is the culminating event of the iGEM 2015 competition season. This 5-day event showcases synthetic biology achievements of both collegiate and high school participating teams spanning all disciplines, backgrounds and interests. The Jamboree features team presentations and exhibition hall poster sessions, workshops, networking sessions, panel discussions, an award ceremony and much more!  For more on the iGEM experience see our video compilation of iGEM teams, their projects and experiences.

Deadline: Host a WORKSHOP at the iGEM Giant Jamboree (advanced registration deadline)

0
0

Workshop opportunities at the iGEM Giant Jamboree

***Deadline: Advanced registration: May 22, 2015!

Host a workshop at the Giant Jamboree and have all attention on you!

This unique opportunity gives you the platform to address the iGEM audience of 100+ attendees all at once. Ideal for demonstrations or presentations to promote your product, service or initiative.

With Advanced registration your workshop can be promoted in our event registration form as part of our official program. We require all event attendees to register via this form so all attendees would see your workshop!

Workshop session are 75 minutes

Single session, day and weekend packages available 

For more information on workshops and how to participate please click here or contact us at hq@igem.org

 

More on iGEM:

iGEM, the International Genetically Engineered Machine Competition, a non-profit organization and a community of over 18,000 young scientists and leaders in synthetic biology. Inspiring learning and innovation in synthetic biology through competition, the iGEM program is the premiere synthetic biology competition for both university and high school students.

Our main event, the Giant Jamboree, held on September 24-28, 2015, Boston, MA, is the culminating event of the iGEM 2015 competition season. This 5-day event showcases synthetic biology achievements of both collegiate and high school participating teams spanning all disciplines, backgrounds and interests.

The Jamboree features team presentations and exhibition hall poster sessions, workshops, networking sessions, panel discussions, an award ceremony and much more!  For more on the iGEM experience see our video compilation of iGEM teams, their projects and experiences.

POSTPONED: Changes & Future Trends in the Cambridge Vector of Life Sciences

0
0

This event has been postponed. Stay tuned for a new date!

 

The landscape in greater Kendall Square and MA has changed dramatically in the last decade. With the arrival of big pharma R&D centers starting with Novartis in 2002, the explosion of incubators across MA, and the migration of technology and digital media companies to Cambridge and Boston, we have seen profound and sweeping changes. From accelerating rents to massive new construction projects housing campuses for big pharma R&D, nowhere has this change been more profound than in Cambridge, and the face and fate of Kendall Square has and continues to evolve rapidly. What do these seismic evolutions augur for our future?

Come join us  for a glimpse into the future of Kendall Square and hear a panel of witnesses to the past and oracles for the future discuss how these changes may impact biotech in Cambridge,  especially the community of emerging biotech companies.

Speakers:

  • Peter Abair, Director, Economic Development & Global Affairs, MassBio
  • Steven Gullans, PhD, Managing Director, Excel Medical Ventures, and author of Evolving Ourselves
  • Brad Rosenblum,  Chief Financial & Administrative Officer, Massachusetts Life Sciences Center (MLSC)
  • Jeffrey D. Wager, MD, Chairman & CEO, EnBiotix, Inc.

Moderators:

  • Marc R. Cote, Chief Operating Officer and Co-founder, Accellient Partners, LLC
  • John Hession, Partner,  Morse, Barnes-Brown & Pendleton, PC

 

This Forum is presented by the Entrepreneur's University Forum Working Group.



Bios:

Peter Abair, Director, Economic Development & Global Affairs, MassBio

Peter Abair is MassBio’s Director of Economic and Global Affairs. In his position, he provides consulting services to companies looking to locate to or grow in Massachusetts, manages MassBio's global partners programs, and leads the development and publication of the Industry Snapshot - MassBio's annual economic analysis of the life sciences industry.  Prior to joining MassBio, he served the Commonwealth of Massachusetts in several economic development functions including Director of the Massachusetts Department of Economic Development, Massachusetts Office of Business Development, and Associate Director of the Massachusetts Department of Housing and Community Development. He has served in the administrations of four governors and began his career on the Washington, D.C. staff of the late Congressman Silvio O. Conte.  Peter holds a Bachelor of Arts degree in History and International Relations from Boston University and a Masters in Public Policy and Administration from the University of Massachusetts at Amherst.

Marc R. Cote, Chief Operating Officer and Co-founder, Accellient Partners, LLC
Marc is a partner and co-founder of Accellient Partners, a drug development consulting practice where he is responsible for leading the company's financial, operational and business development activities. Marc is also a co-founder and the Chief Financial Officer of Synchroneuron Inc, a clinical stage VC-backed biopharmaceutical company that is engaged in developing new therapies for tardive dyskinesia (TD).

Marc has extensive experience in helping to launch and operate both start-up and existing ventures. Prior to Accellient, he joined Aptuit Consulting in 2006 when Aptuit founded its global consulting practice.  Prior to Aptuit, he was Vice President of Finance and Shared Services with Dunkin® Brands where he spent a decade in a variety of finance, accounting and shared services roles.  Marc started his career in the Entrepreneurial Services Group at Ernst & Young in Boston where he spent 8 years servicing clients in a variety of industries including venture capital, biotech, high-tech and consulting.

Marc is also an active member of Boston Harbor Angels. In addition, he is a Co-Chair of Mass Bio's Entrepreneur University and a Program Committee Member of The Bioscience Network.

Marc was a licensed CPA in Massachusetts for many years and is a graduate of Bentley College, summa cum laude.

Steve Gullans, PhD, Managing Director, Excel Venture Management

Steve is an experienced investor, entrepreneur, author, and scientist.  At Excel, he focuses on life science technology companies with a particular interest in disruptive platforms.  Steve was a faculty member at Harvard Medical School and Brigham and Women's Hospital for nearly 20 years. He published more than 130 scientific papers touching many areas of biology and medicine, lectured internationally, and co-authored numerous patents. He and Juan Enriquez recently co-authored Evolving Ourselves: How Unnatural Selection and Non-Random Mutation are Changing Life on Earth. Steve’s current and prior investments and board directorships include Tetraphase Pharmaceuticals [TTPH], Molecular Templates, Cleveland HeartLab, nanoMR, BioTrove, Biocius, Activate Networks, and RxGen, where he was also co-founder and CEO. Steve received his B.S. at Union College, Ph.D. at Duke University, and postdoctoral training at the Yale School of Medicine. He is a Fellow of the AAAS and the AHA.

John Hession, Partner, Morse, Barnes-Brown & Pendleton, P.C.
Mr. Hession is a Partner at Morse, Barnes-Brown & Pendleton, P.C., and a member of the Corporate, Venture Capital and Life Sciences practice groups at the firm’s Waltham office. He recently joined the firm in February of 2015, after an eight-year tenure at Cooley LLP.  John was a co-founder of Cooley's Boston office, and served as Managing Partner of the Boston office for its first two years of operation, helping grow the firm from ten to seventy-plus professionals and staff.  John Hession represents emerging-growth companies, principally in the life sciences, medical device, software and digital media fields, as well as angels and venture capital funds in the investment process in these areas. His practice includes both start-up and later-stage company work; equity-based compensation strategies; mergers and acquisitions, representing either buyers or sellers; corporate partnering, joint ventures, collaboration and development deals, and other strategic alliances involving technology transfers; license and distribution arrangements for medical devices and biotechnology, software and hardware companies; and venture capital or angel financings of technology companies, representing either investors or companies.

Bradley Rosenblum, Chief Financial & Administrative Officer, Massachusetts Life Sciences Center
Brad Rosenblum joined the MLSC in 2009. In his role, Brad oversees the financial and administrative functions of the MSLC, manages the MLSC’s Tax Incentive Program, and oversees the MLSC’s early-stage portfolio. Before joining the MLSC, Brad worked in a variety of finance roles for public- and venture-funded companies. He earned a Bachelor’s degree from the University of Massachusetts at Amherst and an MBA from Boston University. He is a licensed CPA in the Commonwealth of Massachusetts.

Jeffrey D. Wager, MD, Chairman & CEO, EnBiotix, Inc.
Jeffrey Wager has 23 years of senior operating experience in the life sciences, beginning his career with a unit of the Bank of Tokyo, advising Japanese pharma companies on the design and conduct of international clinical trials and strategic alliances.  He then was part of Medical Science Partners, a $100 million Harvard sponsored VC fund focused on startups spinning out of the Harvard medical system, helping to create and manage a portfolio of 30 companies.

In 2000, he formed Apeiron Partners LLC, focusing on corporate spin-outs and VC funds, where he was intimately involved in the design, launch and investment of Z-Cube (€60 million fund created by the Zambon Group in Italy) and the design/execution of six corporate spin-outs - including Targacept, Inc. (NASD:TRGT) and Artisan Pharma, Inc., the latter also as its founding CEO between 2006-2010, raising $50 million, building the entire team and implementing a 750 patient, 17 country Phase 2b/3 study ultimately leading to Artisan’s acquisition by Asahi in 2011.

Dr. Wager is a co-founder and chairman of Proterris, Inc., a therapeutic medical gases company, and an observer to the board of Biotoscana, SL, the largest private equity-backed specialty pharma company in Latin America (2014 revenues - $200 million), which he was instrumental in forming by advising United Medical, Ltda. of Sao Paulo, Brazil on its sale to Biotoscana.


DLA Piper Office Hours at CIC Boston

0
0

CIC Boston is pleased to host Jay Sullivan and Itai Nevo from DLA Piper every other Thursday from 11:00am-12:30pm. Jay and Itai will be on hand to help answer questions about business and legal issues important to entrepreneurs, startups, venture capitalists and angel investors.

DLA Piper is a global law firm with 4,200 lawyers in the Americas, Asia Pacific, Europe and the Middle East; with clients ranging from new and emerging companies developing industry-leading technologies to multinational, Global 1000 and Fortune 500 enterprises.

Itai and Jay represent early stage and emerging growth companies, as well as venture capital, growth equity and private equity investors, in a wide range of general corporate and transactional matters. They work with clients in many industries, including technology & software, healthcare, life sciences, education, cleantech and alternative energy, e-commerce, investment management, financial services, media and telecommunications.

More information and appointment sign-ups here: https://www.dlapiper.com/en/us/special-content-pages/boston-office-hours/

German Consumer Healthcare Market

0
0

Join our free webinar and learn about business opportunities in Europe's largest healthcare market and explore the German OTC business landscape. 

Germany is Europe’s leading OTC (over-the-counter) market in Europe. Sales of non-prescription drugs total more than EUR 7 billion and are showing dynamic growth.

REGISTER HERE:

https://attendee.gotowebinar.com/register/3596743692268921089

Thanks,

Omar Oweiss, Director, Germany Trade and Invest

omar.oweiss@gtai.com

202 629 5713

2015 Massachusetts Life Sciences Innovation Day

0
0

Weathering Healthcare Climate Change

The 8th Massachusetts Life Sciences Innovation (MALSI) Day is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts. This is a high-energy, hands-on event which brings together scientific leaders and business experts to mingle with scientists, post-docs, professors, entrepreneurs, innovators, and venture capitalists.

Our theme this year is “Weathering Healthcare Climate Change” – the environment in which new inventions are commercialized and start-ups are created is constantly and radically changing so how do you make sure that your commercialization plan is robust enough to weather all of the changes that may impact your plan.  Changes in healthcare policy, the economy, available financing, regulatory approvals, and reimbursement all impact a business as it is established and grown.  With so many unknowns, how does the entrepreneur take a best guess at the environment they will be operating in when their new product is ready for market in five, ten or fifteen years.  During 2015’s Mass Life Sciences Innovation Day, our keynotes and panels we will explore the Healthcare Climate Changes that are likely to impact technology development and commercialization and how you can respond.

Learn more & register

WilmerHale Webinar: IP Migration Strategies for Life Sciences Companies

0
0

An increasing number of life sciences companies of all sizes are considering intellectual property migration as an opportunity to achieve legal, tax and operational efficiencies. When considering the adoption of this strategy, it is critically important for executives to understand the requirements and benefits associated with such a reorganization of an IP portfolio. 

During this webinar, WilmerHale Partners Rich Andersen, Steve Barrett and Stuart Falber will discuss:

  • the criteria to determine whether a company is a candidate;
  • the advantages and disadvantages of IP migration;
  • the process for companies to reorganize their IP portfolio; and
  • representative structures as they pertain to life sciences companies.

Participants will have the opportunity to contribute questions online and interact with the panelists during the webinar.

Local AMS Device Manager with DeltaV TRAINING

0
0

AMS Device Manager with DeltaV Training

CEUs: 3.2

Course: June 1 - June 5, 2015

REGISTRATION DEADLINE: May 1, 2015

This 4.5 day course is for instrumentation technicians responsible for all areas of managing and ensuring the reliability of instrumentation in the plant process including startup and commissioning, normal operations, maintenance, and troubleshooting.

The purchase of this course also includes access to the e7020 course at no extra charge and upon confirmed enrollment, the student will receive access to the e7020 online course (via e-mail) to take as a prerequisite prior to attending the instructor led course.

This course is taught by a certified Emerson Process Management instructor in conjunction with the New England Controls office in Massachusetts.

*MassBio members are elligible for a 10% discount off of select DeltaV courses in 2015  - use promo code "MassBio" during registration

Price per student = $4,600 (includes lunch each day & equipment)

Enroll Now!

Data-Driven Decision Making for Biotech & Pharma

0
0

Adaptive 

Data-driven

 

Lessons Over Lunch: FP&A Best Practices

Find out how leading organizations, like Aegerion, Cubist, Pacira, and Gentiva, leverage technology to streamline FP&A processes to drive growth, reduce cost, and ultimately make better decisions.

At this complimentary luncheon, you’ll hear about:

•Key metrics for biotech, their underlying drivers and why they matter

•The importance of real-time visibility into performance and KPIs

•Using analytics and dashboards to communicate performance

REGISTER TODAY TO SECURE YOUR SEAT!

 

Human iPSC Derivation and Culture - a hands-on workshop

0
0

Program presented by the Harvard Stem Cell Institute and the UK Stem Cell Bank.

Learn current reprogramming techniques with this three-day, hands-on course.

Topics include:

  • Hands-on technical training in current reprogramming methodologies
  • Presentation of Sendai virus, episomal vector and mRNA reprogramming
  • Characterization methods for reprogrammed cells
  • Maintaining PSC on feeder free culture
  • Evaluation of PSC cell quality and passaging
  • Banking and Cryopreservation

Space is limited! Register now at: https://hsci.formstack.com/forms/untitled_form4
Workshop cost is: $1200 for HSCI Members | $1,500 for other, non-HSCI academic institutions | $2,200 for industry/commercial participants
This course is held at the HSCI iPS core on the Harvard campus ~ directions and instructions will be sent to confirmed participants


Delegation and Coaching Workshop

0
0

This workshop improves key capabilities for leading and managing more productively and confidently. It is designed for both experienced managers as well as new leaders who want to achieve optimal performance from their teams and reports and advance their careers. It will cover best practices in delegating work to deliver the most effective results, as well as enable leaders and managers to be more productive with their own efforts. This program will promote participants’ ability to provide one-on-one coaching and performance feedback using methods that grow staff capabilities, ensure on-time deliverables, and enhance employee morale.

The format of this program is highly interactive and includes small group discussions of case studies from the life science industry, theoretical overviews, as well as opportunities to practice specific delegation and coaching approaches in role plays during the workshop. The emphasis is on how to positively improve the performance of team members while also maintaining accountability in achieving results.

Topics include:

  • Techniques for Achieving Optimal Performance
  • Fundamentals of Situational Delegation
  • Best Practices for Coaching and Developing Staff
  • Approaches to Improve Performance Feedback

Learn more & register

Whitehead Connects Speaker Series featuring Amy Schulman

0
0
Whitehead Connects featuring Amy Schulman

Venture Partner, Polaris Partners

Ms. Schulman is a Venture Partner at Polaris Partners, serves as CEO of Arsia Therapeutics, an early stage biotech company, and is Executive Chair of SQZ Biotech.  Read more below.

How to Cross the Street:  Lessons I’ve Learned from a Noisy Intersection

June 2, 2015
5:30 pm presentation; 6:30 pm networking reception
Whitehead Institute
Nine Cambridge Center, Cambridge, MA 0214

About Whitehead Connects

Whitehead Connects is an initiative that brings renowned biology and biotech leaders to Whitehead Institute for an engaging presentation and dynamic networking opportunity for participants.  Following the free, public lecture participants will have the opportunity to meet Whitehead postdoctoral fellows and learn about their latest discoveries.  

Overcoming Challenges in Rare Disease Research Part I: Will Innovation & Technology “Bridge” the Gaps in Translational Medicine for Orphan Diseases?

0
0

There are more than 3000 diseases classified as “orphan diseases” and 300 approved medicines for the treatment of these diseases.

While regulatory approvals for orphan drugs are at an all time high there are still significant challenges in bringing innovative medicines to patients. A sense of urgency to develop effective treatments for orphan diseases is exemplified by the actions of passionate patient advocacy groups demanding changes in the drug development and regulatory processes to approve innovative treatments for orphan diseases.

Come join us to hear our panel discuss challenges in the development of preclinical models for orphan diseases and address such questions as:

  • How are new technologies being leveraged to facilitate target identification and led optimization?
  • What are the risks associated with these new paths towards clinical development?
  • What are the challenges from a regulatory and clinical design perspective as we bring new technologies into clinical development?
  • Are there ways to derisk innovative treatments more quickly in the orphan disease space ?

In Part II we will carry the discussion forward from proof of concept studies to market approval as we explore the many challenges and solutions found on the development side of rare disease research.  

Speakers:

  • James McArthur, PhD, Founder and Chief Scientific Officer, Cydan Development
  • Alonso Ricardo, PhD, Senior Director R&D, Ra Pharmaceuticals
  • Joe Sypek, PhD, Director, Discovery Research, Shire Pharmaceuticals

Moderator:

  • Steven Perrin, PhD, Chief Executive Officer and Chief Scientific Officer, ALS Therapy Development Institute (ALS TDI)


Speaker Bios:


James McArthur, PhD, Founder and Chief Scientific Officer, Cydan Development
Dr. McArthur is a founder and the Chief Scientific Officer of Cydan Development, an accelerator for the development of therapeutics for rare diseases, and a member of the Friedreich’s Ataxia Research Alliance (FARA) Scientific Advisory Board and Board of Directors. Dr. McArthur is also a founder of Vtesse Inc, a biotechnology company developing treatments for lysosomal storage diseases, including Niemann Pick disease type C, and he was the founding employee and Chief Scientific Officer of Synovex Corp, now Adheron Therapeutics, focused on fibroblast mediated diseases. Previously, Dr. McArthur served as Vice President of Preclinical Development for Phylogix Inc, a stem cell biology company, and was the Acting Head of Research and Principal Scientist at Cell Genesys Inc. developing gene therapeutics for the treatment of genetic diseases and cancers. In addition, Dr. McArthur was a Senior Scientist at Somatix Therapy, which was acquired by Cell Genesys.

Dr. McArthur received his BSc in biochemistry and PhD in molecular oncology from McGill University in Montreal and was a postdoctoral fellow at the Massachusetts Institute of Technology in Cambridge and the University of California, Berkeley. He has published and patented work in the areas of immunology, gene therapy, genetic diseases, vascular biology and oncology and during his career, he has consulted for venture capital groups and biotechnology companies in diverse therapeutic areas

Steven Perrin, PhD, Chief Executive Officer and Chief Scientific Officer, ALS Therapy Development Institute (ALS TDI)
Steven Perrin earned his Ph.D. at Boston University Medical Center studying the transcriptional regulation of genes during adipocyte and myocyte differentiation. Steven moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen Idec. He joined ALS TDI in 2007 as part of historical collaboration between the Muscular Dystrophy Association, Augie's Quest and ALS TDI to develop effective therapeutics for ALS patients. Since joining ALS TDI Steven has spearheaded the development of computational biology capabilities and information management systems to more clearly understand the molecular mechanisms associated with disease onset and progression in neurodegenerative diseases. He has expanded ALS TDI's drug screening program to include expertise in the generation and assessment of gene therapy vectors and protein biologics in preclinical models of neurodegeneration. He has developed a business plan to facilitate pharmaceutical partnerships for rapid clinical development and commercialization of promising targets for ALS patients. Steven is a frequent participant in international conferences in computational biology, genomics, drug development, and neurodegeneration.

Alonso Ricardo, PhD, Senior Director R&D, Ra Pharmaceuticals
Alonso Ricardo joined Ra in 2010 and has held a variety of roles with increasing responsibility. Alonso received a Ph.D. in Chemistry from the University of Florida working under the supervision of Professor Steven A. Benner. Following graduation, he joined the faculty of the Universidad de los Andes in Bogota, Colombia where he performed research in peptide macrocyclization and Bioorganic Chemistry. In 2006 he became an HHMI Research Associate with Professor Jack W. Szostak, working in Synthetic Biology at Harvard University and the Massachusetts General Hospital.

Joe Sypek, PhD, Director, Discovery Research, Shire Pharmaceuticals
As External Science Lead at Shire, Joe's current role is to identify, initiate, and foster new and ongoing academic alliance partnerships to feed the early discovery stage pipeline in the Rare Disease space within Shire’s Discovery Biology and Translational Research.  Joe has more than 25 years of experience in leadership, drug discovery research and development (small molecules & biologics) in both academia (Tufts University, Boston University) and the biopharmaceutical industry (Genetics Institute, Wyeth, Pfizer, The Research Network, and now Shire). He has a broad range of expertise working in innate and cell-mediated immunity, cytokine and protease biology, and with animal models of disease (asthma/COPD, lupus, inflammation, & intracellular infections).

He completed his postdoctoral and doctoral training in immunology at Tufts University (Sackler School Graduate Biomedical Sciences), and in marine science and comparative immunology at the College of William & Mary, respectively. He has co-authored many peer-reviewed papers, IND supporting documents, and has published several patents. He is a member of American Association of Immunology (AAI), American Thoracic Society (ATS), European Respiratory Society (ERS), Inflammation Research Association (IRA), and Association for Women in Science (AWIS) where he has mentored several Mentoring Circles.

Regional Mixer: Waltham

0
0

MassBio is committed to supporting our members throughout the Greater Boston area, and we look forward to bringing our popular Regional Mixer Series on the road again in 2015. At this Regional Mixer, we showcase Waltham as a great place for life sciences companies to do business.

This is also an opportunity to learn more about MassBio. If you are a member, you can learn how we can help you. If you are not a member, come to learn why you should join! Stop by on your way home to mingle with other members of the life sciences community!

 

This event is sponsored by:

 

MBBP

 

 

janitronics

Audits of 401K Plans

0
0

401(k) plans are a popular option for employee benefit plans, so you must have the proper skills to audit these plans effectively. Every aspect of how to audit a 401(k) plan and prepare financial statements that satisfy ERISA and SEC requirements are covered in this course. Tap into ways to plan and conduct 401(k) audits more efficiently and effectively and understand the differences between 401(k) audits and other employee benefit plan audits.

Learn more & register.

Viewing all 2057 articles
Browse latest View live




Latest Images